

Supplementary Information

Small Molecule Drugs That Inhibit Phagocytosis

Melika Loriani^{1,2}, Melissa M. Lewis-Bakker³, Kayluz Frias Boligan¹, Siming Wang³,
Mairead B. Holton¹, Lakshmi P. Kotra^{3,4,*} and Donald R. Branch^{1,2,5,6,*}

¹ Centre for Innovation, Canadian Blood Services, Toronto, ON M5G 2M1, Canada

² Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A8, Canada

³ Krembil Research Institute, University Health Network, Toronto, ON M5G 1L7, Canada

⁴ Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON M5S 3M2, Canada

⁵ Department of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada

⁶ Keenan Research Centre, Canadian Blood Services, Toronto, ON M5B 1W8, Canada

*Correspondence: p.kotra@utoronto.ca (L.P.K.); don.branch@utoronto.ca (D.R.B.);

Tel.: +1-416-581-7602 (L.P.K.); +1-416-313-4458 (D.R.B.)




Figure S1. Unpublished 3rd generation structures based on merging the features of KB-55, KB-57 [6] and KB-59 [6].




Figure S2. ^1H -NMR spectrum of KB-151 obtained using the method as described in Section 4.2 of main text.




Figure S3. ^1H -NMR spectrum of KB-198 obtained using the method as described in Section 4.2 of main text.




Figure S4. ^1H -NMR spectrum of KB-208 obtained using the method as described in Section 4.2 of main text.




Figure S5. ^1H -NMR spectrum of KB-210 obtained using the method as described in Section 4.2 of main text.




Figure S6. UHPLC-HRMS/MS spectrum of **KB-151** obtained using the method as described in Section 4.3 of main text. **(A)** MS1 and **(B)** MS2.




Figure S7. UHPLC-HRMS/MS spectrum of **KB-198** obtained using the method as described in Section 4.3 of main text. (A) MS1 and (B) MS2.




Figure S8. UHPLC-HRMS/MS spectrum of **KB-208** obtained using the method as described in Section 4.3 of main text. (A) MS1 and (B) MS2.





Figure S9. UHPLC-HRMS/MS spectrum of **KB-210** obtained using the method as described in Section 4.3 of main text. **(A)** MS1 and **(B)** MS2.

Table S1. Purity results of hit compounds using methods as described in Section 4.4 of main text.

Chemical Compound	Purity (%)	
	Method A	Method B
KB-151	95	97
KB-198	98	96
KB-208	95	95
KB-210	99	97

(A)



(B)





Figure S11. HPLC-PDA spectrum of **KB-151** using the method as described in Section 4.4 of main text. (A) Method A and (B) Method B.

(A)



(B)





Figure S12. HPLC-PDA chromatogram of **KB-198** using the method as described in Section 4.4 of main text. (A) Method A and (B) Method B.

(A)



(B)





Figure S13. HPLC-PDA spectrum of **KB-198** using the method as described in Section 4.4 of main text. (A) Method A and (B) Method B.

(A)



(B)




Figure S14. HPLC-PDA chromatogram of **KB-208** using the method as described in Section 4.4 of main text. (A) Method A and (B) Method B.





Figure S15. HPLC-PDA spectrum of **KB-208** using the method as described in Section 4.4 of main text. (A) Method A and (B) Method B.

(B)



(A)





Figure S16. HPLC-PDA chromatogram of **KB-210** using the method as described in Section 4.4 of main text. (A) Method A and (B) Method B.

(A)



(B)




Figure S17. HPLC-PDA spectrum of **KB-210** using the method as described in Section 4.4 of main text. (A) Method A and (B) Method B.

Reference

6. Purohit, M.K.; Chakka, S.K.; Scovell, I.; Neschadim, A.; Bello, A.M.; Salum, N.; Katsman, Y.; Bareau, M.C.; Branch, D.R.; Kotra, L.P. Structure-activity relationships of pyrazole derivatives as potential therapeutics for immune thrombocytopenias. *Bioorg. Med. Chem.* **2014**, *22*, 2739–2752. <https://doi.org/10.1016/j.bmc.2014.03.016>.